Search Results for "Infectious Uveitis"
Original Source: Infectious Uveitis
Uveitis may be caused by infectious or non-infectious disorders. Although most cases of uveitis are considered to be immune-mediated disorders, certain forms of uveitis are caused by infectious agents. The disease may become latent, smoldering and chroni...
Matching Channels
Uveitis may be caused by infectious or non-infectious disorders. Although most cases of uveitis are considered to be immune-mediated disorders, certain forms of uveitis are caused by infectious agen...
There are many different types of Uveitis. This is because: * The Uvea is made up of different parts. So if the iris is affected, the condition and its treatment could be totally different to when...
Matching News
XOMA receives Orphan Drug Designation for eye disease treatment
US therapeutic antibodies company XOMA Corporation has announced that its IL-1 beta modulating antibody gevokizumab has been granted Orphan Drug Designation by the FDA for the treatment of non-infecti...
Isotechnika keeps voclosporin focus on nephrology after failure in uveitis
Lux Biosciences finally has ended its pursuit of US FDA approval for oral voclosporin in the treatment of non-infectious uveitis after the calcineurin inhibitor failed to meet its primary endpoint in...
Xoma begins two new studies for gevokizumab in uveitis and osteoarthritis
Xoma soon will have four clinical trials under way for its interleukin-1 beta (IL-1 beta) antibody gevokuzimab, including a Phase III trial in non-infectious uveitis and a Phase II study in erosive o...
FDA Grants Orphan Drug Status to Gevokizumab
The FDA has granted orphan drug designation to gevokizumab for the treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis, or chronic noninfectious anterior uveitis. Orpha...
[Xoma] nets $37.6mm through FOPO
[Xoma Corp.] (antibodies) has netted $37.6mm though the follow-on public offering of 13.3mm common shares at $3. The company will use some of the funds for ongoing development of gevokizumab with its...
Lux Biosciences Completes Enrollment in Phase 3 Study of Non-infectious Uveitis Drug Candidate ...
BERKELEY, Calif., Oct. 3, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced it has opened enrollment in a Phase 3 clinical trial, titled A randomizEd, double-masked, placebo-con...
Lux completes recruitment for study of uveitis drug Luveniq
Lux BioSciences completed enrollment for a late-stage trial of uveitis drug candidate Luveniq, or oral voclosporin, which is -More-
Matching PubMed Articles
Identification of New Pathogens in the Intraocular Fluid of Patients With Uveitis.
PURPOSE: To determine infectious causes in patients with uveitis of unknown origin by intraocular fluids analysis. DESIGN: Case-control study. METHODS: Ocular fluids from 139 patients suspected of inf...
Uveitis in Seronegative Arthritis.
Uveitis is the most frequent extra-articular feature in seronegative arthritis and is part of the classification criteria for spondyloarthritis. Recent studies confirm a prevalence of up to one third...
Smoking complicates the course of non-infectious uveitis.
BACKGROUND: Data concerning the association of smoking and uveitis are limited. The aim of this study was to evaluate the effect of tobacco smoking on uveitis activity and complications of noninfectio...
Psoriasis and uveitis: a literature review.
Psoriasis is a systemic, chronic, immunologically mediated disease, with significant genetic and environmental influences. It affects from 1 to 3% of the world population. Recently, the relation betwe...
Infectious causes of posterior uveitis and panuveitis in Thailand.
PURPOSE: To determine the infectious causes of posterior uveitis (PU) and panuveitis (panU) in Thailand. METHODS: We investigated the infectious causes of uveitis involving the posterior segment of th...
